Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(4)
•••
Comment by Marky1on Dec 24, 2019 11:07pm
480 Views
Post# 30489355

RE:Price after enrollment and study completion

RE:Price after enrollment and study completionGreat question...I feel that there will be 5 factors  which will propel this stock to 5$ CDN IMHO

1) announcement of final enrolment of the last patient in the P2b testing...Up to  0.80$..early to mid January

2) 4 weeks later top notch results from the P2 testing....1.20$ by early to mid February 

3) notice of successful IND with the FDA....This allows the new drug 346 to be exported and tested in the USA.... 1.50$ ...Sometime in March ...

4) Teaming up with a Big Pharma in the USA for beginning of Phase 3 testing.....$2.00 to $2.50$  May 2020

5) buyout by a Big Pharma...5$ by Ed of 2029....I base this my theoretically putting the value of ATB 346 at  $1B USD.....roughly 10% of the NSAIDS industry...or $5 CDN


Merry Christmas! Wish I had kids to celebrate with!
stay safe and healthy
Marky1
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities